NEW ORLEANS — Low-dose naltrexone decreased ocular pain and improved quality of life in patients with neuropathic corneal pain, according to Pam Theriot, OD, of Blink Eye Spa, who evaluated recent dry eye clinical research at SECO 2022.
Researchers from Tufts University published a study in Ocular Surface that evaluated one daily dose of 4.5 mg of naltrexone in patients with neuropathic corneal pain, which is caused by damage or disease of the somatosensory nervous system that innervates the cornea (Dieckmann et al.).
“This is a drug that’s been around for a long time,”